GSK announces FDA Advisory Committee vote in favour of raxibacumab for the treatment of inhalational anthrax infection
2 November 2012 | By GlaxoSmithKline
Anthrax has been identified as a serious potential threat...
List view / Grid view
2 November 2012 | By GlaxoSmithKline
Anthrax has been identified as a serious potential threat...
31 October 2012 | By GlaxoSmithKline
“GSK fully supports the commitment made by BMJ to drive greater transparency of clinical trial data..."
30 October 2012 | By GlaxoSmithKline
GlaxoSmithKline announced the start of a Phase III programme...
22 October 2012 | By GlaxoSmithKline
Results from five Phase III studies were presented at the IVW congress...
11 October 2012 | By GlaxoSmithKline
Greater openness, transparency and collaboration...
9 October 2012 | By GlaxoSmithKline
GSK welcomes the announcement from GAVI Alliance...
4 October 2012 | By GlaxoSmithKline
Dolutegravir is not yet approved as a treatment for HIV...
1 October 2012 | By GlaxoSmithKline
The pivotal Phase III study COMPARZ has met its primary endpoint...
26 September 2012 | By GlaxoSmithKline
GSK announces the following changes to its Board and Committee structure...
26 September 2012 | By GlaxoSmithKline
Japanese New Drug Application (JNDA) submitted for COPD and asthma....
17 September 2012 | By GlaxoSmithKline
GSK has submitted a regulatory application in the European Union seeking approval of an additional indication for Synflorix™...
13 September 2012 | By GlaxoSmithKline
GlaxoSmithKline has acquired five million newly issued shares of Response Genetics Inc...
24 August 2012 | By GlaxoSmithKline
GSK confirms its intention to commence global filings from the end of 2012...
23 August 2012 | By GlaxoSmithKline
“The start of the Phase III programme in rheumatoid arthritis is an important milestone in our collaboration with Janssen Biologics.”
15 August 2012 | By GlaxoSmithKline
GSK has reached agreement to divest the majority of its “Classic Brands” in Australia...